News

The Warren Center for Neuroscience Drug Discovery at Vanderbilt University consists of a remarkable community dedicated to advancing the translation of basic science to novel therapeutics to treat serious brain disorders. In addition to our outstanding faculty, postdocs, and trainees who are at the forefront of our cutting-edge research,… Read More

The Warren Center for Neuroscience Drug Discovery at Vanderbilt University consists of a remarkable community dedicated to advancing the translation of basic science to novel therapeutics to treat serious brain disorders. In addition to our outstanding faculty, postdocs, and trainees who are at the forefront of our cutting-edge research, a… Read More

The Vanderbilt Kennedy Center has awarded Colleen Niswender (Pharmacology, Warren Center for Neuroscience Drug Discovery) a 2025–26 Nicholas Hobbs Discovery Award for her Rett Syndrome research and advocacy. Read More

The Warren Center for Neuroscience Drug Discovery at Vanderbilt University consists of a remarkable community dedicated to advancing the translation of basic science to novel therapeutics to treat serious brain disorders. In addition to our outstanding faculty, postdocs, and trainees who are at the forefront of our cutting-edge research, a… Read More

A new potential treatment for schizophrenia discovered through the Warren Center for Neuroscience Drug Discovery has entered Phase 1 clinical trials, marking the fifth WCNDD therapeutic to advance into human testing.   Read more here. Read More

We are thrilled to congratulate our colleagues at WCNDD, Dr. Kayla Temple and Dr. Darren Engers, on being named 2025 Master Innovators by Vanderbilt University! Kayla, as Senior Drug Discovery Scientist and Assistant Director of Medicinal Chemistry, has built an impressive portfolio with 35… Read More

Neumora Therapeutics has initiated a Phase 1 clinical study of NMRA-898, a second-generation M4 muscarinic receptor positive allosteric modulator (PAM) that originated from research conducted in collaboration with the Warren Center for Neuroscience Drug Discovery (WCNDD). This first-in-human study evaluates the safety, tolerability, and pharmacokinetics of NMRA-898… Read More